New at WaveTec

Article

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

“The board appreciates Tom Berryman’s leadership and great contribution to the company's achievements, as well as his role in recruiting Tom Frinzi to the company. We are enormously pleased to welcome Tom to WaveTec,”said Charles Warden, of Versant Ventures a board member and investor in WaveTec. “Tom is a seasoned and dynamic leader who brings a wealth of proven commercial experience within the ophthalmic space. ”

Frinzi who began his career at Johnson & Johnson, is a 30 year veteran of the ophthalmic and medical device industries. Most recently, he served as Vice President of Global Commercial Operations at Bausch+Lomb Surgical where he was responsible for worldwide revenue of approximately $500 million generated via their cataract and vitreo‐retinal product portfolio.

“What attracted me to WaveTec is the potential to change the landscape of cataract surgery,” said Mr Frinzi. “What cornea topography was to refractive surgery, ORange can be to cataract surgery. The Premium Channel has raised expectations and WaveTec is uniquely positioned to help surgeons optimize their outcomes and ultimately improve the overall patient experience. That's exciting.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.